X-linked myotubular myopathy: A prospective international natural history study
<p><strong>Objectives:</strong><br /> Because X-linked myotubular myopathy (XLMTM) is a rare neuromuscular disease caused by mutations in the MTM1 gene with a large phenotypic heterogeneity, to ensure clinical trial readiness, it was mandatory to better quantify disease burde...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Academy of Neurology
2019
|
| _version_ | 1797060531807322112 |
|---|---|
| author | Servais, L Annoussamy, M Lilien, C Gidaro, T Gargaun, E Chê, V Schara, U Gangfuß, A D'Amico, A Dowling, JJ Darras, BT Daron, A Hernandez, A de Lattre, C Arnal, J-M Mayer, M Cuisset, J-M Vuillerot, C Fontaine, S Bellance, R Biancalana, V Buj-Bello, A Hogrel, J-Y Landy, H |
| author_facet | Servais, L Annoussamy, M Lilien, C Gidaro, T Gargaun, E Chê, V Schara, U Gangfuß, A D'Amico, A Dowling, JJ Darras, BT Daron, A Hernandez, A de Lattre, C Arnal, J-M Mayer, M Cuisset, J-M Vuillerot, C Fontaine, S Bellance, R Biancalana, V Buj-Bello, A Hogrel, J-Y Landy, H |
| author_sort | Servais, L |
| collection | OXFORD |
| description | <p><strong>Objectives:</strong><br /> Because X-linked myotubular myopathy (XLMTM) is a rare neuromuscular disease caused by mutations in the MTM1 gene with a large phenotypic heterogeneity, to ensure clinical trial readiness, it was mandatory to better quantify disease burden and determine best outcome measures.</p><br />
<p><strong>Methods:</strong><br /> We designed an international prospective and longitudinal natural history study in patients with XLMTM and assessed muscle strength and motor and respiratory functions over the first year of follow-up. The humoral immunity against adeno-associated virus serotype 8 was also monitored.</p><br />
<p><strong>Results:</strong><br /> Forty-five male patients aged 3.5 months to 56.8 years were enrolled between May 2014 and May 2017. Thirteen patients had a mild phenotype (no ventilation support), 7 had an intermediate phenotype (ventilation support less than 12 hours a day), and 25 had a severe phenotype (ventilation support 12 or more hours a day). Most strength and motor function assessments could be performed even in very weak patients. Motor Function Measure 32 total score, grip and pinch strengths, and forced vital capacity, forced expiratory volume in the first second of exhalation, and peak cough flow measures discriminated the 3 groups of patients. Disease history revealed motor milestone loss in several patients. Longitudinal data on 37 patients showed that the Motor Function Measure 32 total score significantly decreased by 2%. Of the 38 patients evaluated, anti–adeno-associated virus type 8 neutralizing activity was detected in 26% with 2 patients having an inhibitory titer >1:10.</p><br />
<p><strong>Conclusions:</strong><br /> Our data confirm that XLMTM is slowly progressive for male survivors regardless of their phenotype and provide outcome validation and natural history data that can support clinical development in this population.</p><br />
<p><strong>ClinicalTrials.gov Identifier:</strong> NCT02057705.</p> |
| first_indexed | 2024-03-06T20:18:28Z |
| format | Journal article |
| id | oxford-uuid:2cf93888-883c-4816-8cc8-f0449ec9d538 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:18:28Z |
| publishDate | 2019 |
| publisher | American Academy of Neurology |
| record_format | dspace |
| spelling | oxford-uuid:2cf93888-883c-4816-8cc8-f0449ec9d5382022-03-26T12:40:07ZX-linked myotubular myopathy: A prospective international natural history studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2cf93888-883c-4816-8cc8-f0449ec9d538EnglishSymplectic ElementsAmerican Academy of Neurology2019Servais, LAnnoussamy, MLilien, CGidaro, TGargaun, EChê, VSchara, UGangfuß, AD'Amico, ADowling, JJDarras, BTDaron, AHernandez, Ade Lattre, CArnal, J-MMayer, MCuisset, J-MVuillerot, CFontaine, SBellance, RBiancalana, VBuj-Bello, AHogrel, J-YLandy, H<p><strong>Objectives:</strong><br /> Because X-linked myotubular myopathy (XLMTM) is a rare neuromuscular disease caused by mutations in the MTM1 gene with a large phenotypic heterogeneity, to ensure clinical trial readiness, it was mandatory to better quantify disease burden and determine best outcome measures.</p><br /> <p><strong>Methods:</strong><br /> We designed an international prospective and longitudinal natural history study in patients with XLMTM and assessed muscle strength and motor and respiratory functions over the first year of follow-up. The humoral immunity against adeno-associated virus serotype 8 was also monitored.</p><br /> <p><strong>Results:</strong><br /> Forty-five male patients aged 3.5 months to 56.8 years were enrolled between May 2014 and May 2017. Thirteen patients had a mild phenotype (no ventilation support), 7 had an intermediate phenotype (ventilation support less than 12 hours a day), and 25 had a severe phenotype (ventilation support 12 or more hours a day). Most strength and motor function assessments could be performed even in very weak patients. Motor Function Measure 32 total score, grip and pinch strengths, and forced vital capacity, forced expiratory volume in the first second of exhalation, and peak cough flow measures discriminated the 3 groups of patients. Disease history revealed motor milestone loss in several patients. Longitudinal data on 37 patients showed that the Motor Function Measure 32 total score significantly decreased by 2%. Of the 38 patients evaluated, anti–adeno-associated virus type 8 neutralizing activity was detected in 26% with 2 patients having an inhibitory titer >1:10.</p><br /> <p><strong>Conclusions:</strong><br /> Our data confirm that XLMTM is slowly progressive for male survivors regardless of their phenotype and provide outcome validation and natural history data that can support clinical development in this population.</p><br /> <p><strong>ClinicalTrials.gov Identifier:</strong> NCT02057705.</p> |
| spellingShingle | Servais, L Annoussamy, M Lilien, C Gidaro, T Gargaun, E Chê, V Schara, U Gangfuß, A D'Amico, A Dowling, JJ Darras, BT Daron, A Hernandez, A de Lattre, C Arnal, J-M Mayer, M Cuisset, J-M Vuillerot, C Fontaine, S Bellance, R Biancalana, V Buj-Bello, A Hogrel, J-Y Landy, H X-linked myotubular myopathy: A prospective international natural history study |
| title | X-linked myotubular myopathy: A prospective international natural history study |
| title_full | X-linked myotubular myopathy: A prospective international natural history study |
| title_fullStr | X-linked myotubular myopathy: A prospective international natural history study |
| title_full_unstemmed | X-linked myotubular myopathy: A prospective international natural history study |
| title_short | X-linked myotubular myopathy: A prospective international natural history study |
| title_sort | x linked myotubular myopathy a prospective international natural history study |
| work_keys_str_mv | AT servaisl xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT annoussamym xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT lilienc xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT gidarot xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT gargaune xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT chev xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT scharau xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT gangfußa xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT damicoa xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT dowlingjj xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT darrasbt xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT darona xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT hernandeza xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT delattrec xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT arnaljm xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT mayerm xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT cuissetjm xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT vuillerotc xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT fontaines xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT bellancer xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT biancalanav xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT bujbelloa xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT hogreljy xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy AT landyh xlinkedmyotubularmyopathyaprospectiveinternationalnaturalhistorystudy |